Ipamorelin 5mg & 10mg – A synthetic pentapeptide growth hormone secretagogue (GHS) and selective ghrelin receptor (GHS-R1a) agonist. Research demonstrates ipamorelin induces GH release from primary rat pituitary cells (EC₅₀ = 1.3 nM) and increases plasma GH levels in animal models without significantly affecting cortisol, prolactin, FSH, LH, or TSH levels . This targeted receptor specificity makes ipamorelin a valuable tool for studies exploring growth hormone pathways with minimal off-target endocrine effects. Available in 5mg and 10mg research quantities.
Looking to buy Ipamorelin for your research? Our lab-verified >98% pure Ipamorelin peptide is trusted by researchers worldwide for growth hormone release, metabolic, and endocrine research studies. In stock – ready to ship within 24 hours.
✅ Lab-Tested >98% Purity (COA Included)
✅ 5mg & 10mg Vials Available
✅ Selective Ghrelin Receptor Agonist
✅ Fast, Discreet Shipping Worldwide
✅ Trusted by Leading Research Institutions
Ipamorelin is a synthetic pentapeptide and a member of the growth hormone-releasing peptide (GHRP) class. It is a potent and selective ghrelin receptor (GHS-R1a) agonist that stimulates the release of growth hormone (GH) from the pituitary gland.
When you buy Ipamorelin from Mega Protide, you’re getting a research-grade peptide that has been third-party tested for purity and potency. This Ipamorelin research peptide is widely used in endocrine, metabolic, and growth hormone research.
| Parameter | Details |
|---|---|
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH₂ |
| One-Letter Code | AIBHD2NALfK-NH₂ |
| Molecular Formula | C₃₈H₄₉N₉O₅ |
| Molecular Weight | ~711.9 g/mol |
| CAS Number | 170851-70-4 |
| Synonyms | NNC 26-0161 |
| Form | Lyophilized powder |
| Quantity | 5mg or 10mg per vial |
| Purity | >98% by HPLC |
| Storage | Store at -20°C for long-term; 4°C for 2-7 days after reconstitution |
| Route | Subcutaneous injection |
| Half-Life | ~2 hours |
Ipamorelin exerts its effects through the growth hormone secretagogue receptor (GHS-R1a):
| Mechanism | Effect |
|---|---|
| GHS-R1a Binding | Binds to and activates ghrelin receptors (GHS-R1a) on pituitary cells |
| GH Release | Stimulates pulsatile release of endogenous GH from pituitary somatotrophs |
| Selective Action | Does NOT stimulate FSH, LH, prolactin, TSH, ACTH, or cortisol |
| IP₃ Accumulation | Induces inositol-1,4,5-triphosphate accumulation (EC₅₀ = 46.9 nM) |
| Synergistic Potential | Can be combined with GHRH analogs for synergistic GH release |
| Gastric Emptying | Increases gastric emptying in research models |
Key Advantage: Ipamorelin is highly selective for GH release without affecting other hormonal systems, making it a refined tool for endocrine and metabolic research.
| Parameter | Finding |
|---|---|
| GHS-R1a Binding Affinity | Ki = 63.4 nM |
| IP₃ Accumulation | EC₅₀ = 46.9 nM in BHK cells expressing GHS-R1a |
| GH Release (In Vitro) | EC₅₀ = 1.3 nM in primary rat pituitary cells |
| GH Release (In Vivo – Rats) | ED₅₀ = 80 nmol/kg |
| GH Release (In Vivo – Pigs) | ED₅₀ = 2.3 nmol/kg |
| Gastric Emptying | Increased in rat model of postoperative ileus |
| Bone Growth | Increased body weight and longitudinal bone growth at 18-450 µg/animal |
| Weight Loss Prevention | ~24% inhibition of cisplatin-induced weight loss in ferrets (1-3 mg/kg) |
| Benefit | Research Application |
|---|---|
| Selective GH Release | Studies on GH regulation without affecting other hormones |
| Endocrine Research | Investigations into the ghrelin-GH axis and pituitary function |
| Metabolic Studies | Research on protein synthesis, lipid metabolism, and energy utilization |
| Gastrointestinal Research | Studies on gastric emptying and gut motility |
| Bone Growth Research | Investigations into longitudinal bone growth and tissue regeneration |
| Cachexia Research | Studies on weight loss prevention and muscle preservation |
Researchers choose to buy Ipamorelin from Mega Protide because of our commitment to quality and transparency.
| Application | Research Focus | Status |
|---|---|---|
| GH Regulation | GHS-R1a signaling, GH release dynamics | Extensive research |
| Endocrine Research | Ghrelin-GH axis, pituitary function | Active research |
| Metabolic Research | Protein synthesis, lipid metabolism, energy balance | Active research |
| Gastrointestinal | Gastric emptying, gut motility, postoperative ileus | Preclinical research |
| Bone Growth | Longitudinal bone growth, tissue regeneration | Active research |
| Cachexia Research | Weight loss prevention, muscle preservation | Preclinical research |
| Combination Studies | Synergistic effects with GHRH analogs | Active research |
| Study | Year | Finding |
|---|---|---|
| Raun et al. | 1998 | First characterized Ipamorelin as a selective GHS-R1a agonist with high potency |
| Raun et al. | 2001 | Ipamorelin (EC₅₀ = 1.3 nM) showed GH release similar to GHRP-6 in rat pituitary cells |
| Raun et al. | 2002 | Ipamorelin increased plasma GH in rats (ED₅₀ = 80 nmol/kg) and pigs (ED₅₀ = 2.3 nmol/kg) |
| Venkova et al. | 2002 | Ipamorelin increased gastric emptying in rat postoperative ileus model |
| Bowers et al. | 2003 | Ipamorelin showed high selectivity for GH release without affecting ACTH or cortisol |
| Muccioli et al. | 2004 | Ipamorelin increased body weight and bone growth in rats at 18-450 µg/animal |
| Terova et al. | 2005 | Ipamorelin inhibited cisplatin-induced weight loss by ~24% in ferret model |
📖 Over 25 years of peer-reviewed research support Ipamorelin research utility.
Add 1-2ml bacteriostatic water to the Ipamorelin vial
Gently swirl – do not shake
Refrigerate at 4°C for 2-7 days
For extended storage, aliquot and store below -18°C
Avoid repeated freeze-thaw cycles
Add carrier protein (0.1% HSA or BSA) for long-term storage
| Solvent | Concentration |
|---|---|
| DMF | 30 mg/ml |
| DMSO | 30 mg/ml |
| Ethanol | 30 mg/ml |
| PBS (pH 7.2) | 10 mg/ml |
| Parameter | Recommendation |
|---|---|
| Standard Research Dose | 1-3 mcg/kg per injection |
| Frequency | Once or twice daily |
| Route | Subcutaneous injection |
| Half-Life | ~2 hours |
| Storage | -20°C for long-term; 4°C for 2-7 days after reconstitution |
| Aspect | Details |
|---|---|
| Safety Profile | Well-tolerated; highly selective for GH release |
| Side Effects | Mild injection site reactions possible |
| Hormonal Selectivity | No significant effect on FSH, LH, prolactin, TSH, ACTH, or cortisol |
| Evidence Level | Extensive preclinical research support |
| Long-Term Data | Well-established safety profile in research |
| Storage | Lyophilized: -20°C (long-term); Reconstituted: 4°C for 2-7 days |
| Advantage | Why It Matters |
|---|---|
| Lab-Verified >98% Purity | Third-party HPLC testing ensures quality and consistency |
| 5mg & 10mg Options | Flexible dosing for various research protocols |
| COA Included | Full transparency with every Ipamorelin order |
| Fast Shipping | Orders processed within 24 hours |
| Discreet Packaging | Privacy guaranteed |
Ipamorelin is supplied for research and laboratory use only. Not for human consumption. Not for therapeutic or diagnostic use. Use only by qualified researchers in controlled laboratory settings. Not FDA-approved for human use.
| Weight | 5mg, 10mg |
|---|
Always available!
Comes with each order!
Get access to expert resources.
Reviews
There are no reviews yet.